| Astrocytoma, IDH-Mutant studied in …STUDIED_INderived10 of 25show all (up to 200) |
|---|
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ALIAS · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03528642Phase 1 · active not recruiting Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma · condition mapped ONTOLOGY_EXACT · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07703436Phase 2 · not yet recruiting Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease · condition mapped ONTOLOGY_EXACT · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 3 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831369Phase 2 · recruiting VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma · condition mapped ONTOLOGY_EXACT · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 4 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06860594Phase 1 · recruiting Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma · condition mapped CURATED_BROADER · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07215910Phase 3 · recruiting Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer · condition mapped ONTOLOGY_EXACT · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 3 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04145115Phase 2 · active not recruiting A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden · condition mapped ONTOLOGY_EXACT · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 4 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05303519Phase 3 · recruiting SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) · condition mapped ONTOLOGY_EXACT · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 3 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07544992Phase 1 · recruiting Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas · condition mapped CURATED_BROADER · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 4 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07712757Phase 3 · not yet recruiting Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma · condition mapped ONTOLOGY_EXACT · 25 trials mapped (20 active) | — | — | Astrocytoma, IDH-Mutant, Grade 2 | 1 | Observed | clinicaltrials | graph → |